ClinicalTrials.gg
CompletedNCT00048724Updated Apr 4, 2017Results posted

Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)

A Phase 3 interventional study of peginterferon alfa-2b (SCH 54031) in Chronic Hepatitis C and Cirrhosis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-04.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
631
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
4th of 39
631 · median 99
Started
2002
with 3 others
Phase 3
22 of 40
none open now
Registered
1st of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 4th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2002, is one of 22 in phase 3, and was the 1st registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no treatment for the prevention of disease progression in adult subjects with compensated cirrhosis secondary to chronic hepatitis C, who failed to respond to therapy with an a interferon plus ribavirin.

03

Conditions studied

  • Chronic Hepatitis C
  • Cirrhosis

Keywords

  • Hepatitis C; Cirrhosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age at entry 18-65 years;
  • Non-responders to previous treatment (minimum of 3 months) with an alpha interferon plus ribavirin;
  • Liver demonstrating cirrhosis

Exclusion criteria

Exclusion Criteria:

  • Any other cause for liver disease other than chronic ;
  • History or presence of complications of cirrhosis;
  • Alcohol or illicit drug abuse or treatment with methadone within the past 2 years;
  • Diseases or conditions that could interfere with participation in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
631 participants (actual)

Study arms

  • Experimental
    PegIntron

    PegIntron (peginterferon alfa-2b) 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up

    Biological: peginterferon alfa-2b (SCH 54031)

  • No intervention
    Untreated Control

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Observation of the First Clinical Event Experienced by a Subject

    Clinical events are liver decompensation \[variceal bleeding, development of Child-Pugh Class C, hepatic encephalopathy ≥Grade 2, ascites\], hepatic carcinoma, death, and/or liver transplantation

    Time frame: Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event

Secondary outcomes

  1. Time to Observation of the Disease Progression Experienced by a Subject

    Disease progression was observation of any clinical event defined for the primary outcome, plus any of development of Child-Pugh Class B, emergence of varices, or enlargement of pre-existing varices requiring additional therapy.

    Time frame: Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event

07

Results

Posted Jun 11, 2009

Participant flow

Participant flow — Overall Study
MilestonePegIntronUntreated Control
Started311315
Completed195197
Not completed116118
Withdrew: Adverse event5312
Withdrew: Withdrawal by subject3454
Withdrew: Lost to follow-up55
Withdrew: Protocol-defined clinical event1732
Withdrew: Noncompliance with protocol412
Withdrew: Did not meet protocol eligibility22
Withdrew: Administrative11

Outcome measures

PrimaryTime to Observation of the First Clinical Event Experienced by a Subject

Clinical events are liver decompensation \[variceal bleeding, development of Child-Pugh Class C, hepatic encephalopathy ≥Grade 2, ascites\], hepatic carcinoma, death, and/or liver transplantation

Time frame:
Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event
Reported as:
Number · Participants
Time to Observation of the First Clinical Event Experienced by a Subject
ParticipantsPegIntronUntreated Control
<=6 Months32
>6 to 12 Months55
>12 to 18 Months44
>18 to 24 Months37
>24 to 30 Months76
>30 to 36 Months16
>36 to 42 Months05
>42 to 48 Months20
>48 to 54 Months21
>54 to 60 Months00
Total Over Study2736
Statistical analysis
  • PegIntron vs Untreated Control · Cox Proportional Hazards Model · p = 0.1439 · Hazard ratio (hr): 1.452 · 95% CI 0.880 to 2.396Hazard ratio represents results of untreated control relative to treatment.
SecondaryTime to Observation of the Disease Progression Experienced by a Subject

Disease progression was observation of any clinical event defined for the primary outcome, plus any of development of Child-Pugh Class B, emergence of varices, or enlargement of pre-existing varices requiring additional therapy.

Time frame:
Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event
Reported as:
Number · Participants
Time to Observation of the Disease Progression Experienced by a Subject
ParticipantsPegIntronUntreated Control
<=6 Months1617
>6 to 12 Months66
>12 to 18 Months57
>18 to 24 Months1220
>24 to 30 Months1011
>30 to 36 Months49
>36 to 42 Months24
>42 to 48 Months26
>48 to 54 Months54
>54 to 60 Months13
Total Over Study6387
Statistical analysis
  • PegIntron vs Untreated Control · Cox Proportional Hazards Model · p = 0.0070 · Hazard ratio (hr): 1.564 · 95% CI 1.130 to 2.166Hazard ratio represents results of untreated control relative to treatment.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PegIntron—93/311 (29.9%)290/311 (93.2%)
Untreated Control—74/315 (23.5%)260/315 (82.5%)
Most frequent serious events
Showing 10 of 209
Most frequent serious events
EventPegIntronUntreated Control
HEPATIC NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps)11/31112/315
OESOPHAGEAL VARICES HAEMORRHAGEGastrointestinal disorders0/31110/315
ANAEMIABlood and lymphatic system disorders4/3111/315
CHOLELITHIASISHepatobiliary disorders4/3110/315
GASTROENTERITISInfections and infestations4/3110/315
PNEUMONIAInfections and infestations4/3111/315
VARICES OESOPHAGEALGastrointestinal disorders0/3114/315
CHOLECYSTITISHepatobiliary disorders3/3113/315
HEPATIC NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/3112/315
ALCOHOL ABUSEPsychiatric disorders3/3111/315
Most frequent other events
Showing 10 of 49
Most frequent other events
EventPegIntronUntreated Control
FATIGUEGeneral disorders103/31178/315
HEADACHENervous system disorders103/31147/315
MYALGIAMusculoskeletal and connective tissue disorders76/31119/315
ARTHRALGIAMusculoskeletal and connective tissue disorders68/31163/315
SPLENOMEGALYBlood and lymphatic system disorders60/31154/315
PYREXIAGeneral disorders57/31114/315
THROMBOCYTOPENIABlood and lymphatic system disorders52/31120/315
VARICES OESOPHAGEALGastrointestinal disorders35/31152/315
HEPATOMEGALYHepatobiliary disorders45/31151/315
INSOMNIAPsychiatric disorders50/31145/315

Baseline characteristics

Age, Customized
Age, Customized(Participants)PegIntronUntreated ControlTotal
<=50 years130132262
>50 years181183364
Sex: Female, Male
Sex: Female, Male(Participants)PegIntronUntreated ControlTotal
Female105100205
Male206215421
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, Berg T, Poo JL, Mello CB, Guenther R, Niederau C, Terg R, Bedossa P, Boparai N, Griffel LH, Burroughs M, Brass CA, Albrecht JK; EPIC3 Study Group. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011 Jun;140(7):1990-9. doi: 10.1053/j.gastro.2011.03.010. Epub 2011 Mar 17. Erratum In: Gastroenterology. 2013 Oct;145(4):910. PubMed 21419770 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2002
First posted
Nov 8, 2002
Start
Jun 2002
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Results first posted
Jun 11, 2009
Last update
Apr 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00048724
Responsible party
Sponsor
First posted
Nov 8, 2002
Start date
Jun 2002
Primary completion
Apr 2008
Completion
Apr 2008
Results posted
Jun 11, 2009
Last update
Apr 4, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion